Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 6, 2010, Pages 1273-1280

  Gezsi A ^a   Budde, U ^b   Deak I ^c   Nagy, E ^a   Mohl, A ^a   Schlammadinger, Á ^d   Boda, Z ^d   Masszi, T ^e   Sadler, J E ^f   Bodo I ^e  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Aesculabor Hamburg GmbH   (Germany)

^c Institute of Entrepreneurship and Innovation   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e Szent Laszlo Hospital   (Hungary)

^f WASHINGTON UNIVERSITY   (United States)

Author keywords

Clearance; Von Willebrand disease; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; POLYMER; VON WILLEBRAND FACTOR;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; GENE MUTATION; HALF LIFE TIME; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; SIMULATION; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASE VICENZA;

AMINO ACID SUBSTITUTION; CELL LINE; ELECTROPHORESIS, AGAR GEL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; MALE; PEDIGREE; RECOMBINANT PROTEINS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 77954466579     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03753.x     Document Type: Article

References (24)

1. Mannucci PM, Lombardi R, Castaman G, Dent JA, Lattuada A, Rodeghiero F, Zimmerman TS. von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers. Blood 1988, 71:65-70.
2. Zieger B, Budde U, Jessat U, Zimmermann R, Simon M, Katzel R, Sutor AH. New families with von Willebrand disease type 2M (Vicenza). Thromb Res 1997, 87:57-64.
3. Bodó I, Katsumi A, Tuley E, Schlammadinger Á, Boda Z, Sadler JE. Mutations causing dominant type 1 von Willebrand disease with high penetrance. Blood 1999, 94:373a.
4. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006, 4:2103-14.
5. Casonato A, Pontara E, Sartorello F, Cattini MG, Sartori MT, Padrini R, Girolami A. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002, 99:180-4.
6. Schneppenheim R, Federici AB, Budde U, Castaman G, Drewke E, Krey S, Mannucci PM, Riesen G, Rodeghiero F, Zieger B, Zimmermann R. Von Willebrand Disease type 2M "Vicenza" in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost 2000, 83:136-40.
7. Castaman G, Rodeghiero F, Mannucci PM. The elusive pathogenesis of von Willebrand disease Vicenza. Blood 2002, 99:4243-4. author reply 4
8. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 1987, 7:379-87.
9. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987, 7:2745-52.
10. Matsushita T, Sadler JE. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor. J Biol Chem 1995, 270:13406-14.
11. Lyons SE, Bruck ME, Bowie EJ, Ginsburg D. Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem 1992, 267:4424-30.
12. Raines G, Aumann H, Sykes S, Street A. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res 1990, 60:201-12.
13. Tuley EA, Gaucher C, Jorieux S, Worrall NK, Sadler JE, Mazurier C. Expression of von Willebrand factor "Normandy" an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci USA 1991, 88:6377-81.
14. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, de Groot PG, Denis CV. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004, 279:12102-9.
15. Gézsi A, Mohl A, Sallai K, Nagy E, Szabó T, Sadler JE, Bodó I. Modeling VWF catabolism predicts the multimer pattern and subunit degradation in VWD Vicenza, type 1, type 2A, and healthy controls after DDAVP infusion. J Thromb Haemost 2005, 3:P1476.
16. Castaman G, Missiaglia E, Federici AB, Schneppenheim R, Rodeghiero F. An additional unique candidate mutation (G2470A; M740I) in the original families with von Willebrand disease type 2 M Vicenza and the G3864A (R1205H) mutation. Thromb Haemost 2000, 84:350-1.
17. Schooten CJ, Tjernberg P, Westein E, Terraube V, Castaman G, Mourik JA, Hollestelle MJ, Vos HL, Bertina RM, Berg HM, Eikenboom JC, Lenting PJ, Denis CV. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005, 3:2228-37.
18. Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006, 108:3344-51.
19. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008, 111:4979-85.
20. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008, 111:3531-9.
21. Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost 2003, 1:1714-7.
22. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M, Lombardi R, Mannucci PM. Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra-platelet von Willebrand factor. Eur J Haematol 1988, 40:163-7.
23. Lenting PJ, Vans CJ, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 2007, 5:1353-60.
24. Casonato A, Pontara E, Sartorello F, Cattini MG, Gallinaro L, Bertomoro A, Rosato A, Padrini R, Pagnan A. Identifying type Vicenza von Willebrand disease. J Lab Clin Med 2006, 147:96-102.